CJC-1295 With DAC

Product Overview

CJC-1295 With DAC is a 29-amino acid synthetic GHRH analog enhanced with a Drug Affinity Complex (DAC) — a lysine derivative attached to the C-terminus that enables binding to plasma proteins, extending the peptide's half-life to approximately 8 days. This sustained-release mechanism provides continuous GH stimulation comparable to daily HGH injections, but with less frequent dosing. There are two versions of CJC-1295: With DAC (long-acting, extended half-life, sustained GH release) and Without DAC (short-acting, natural pulsatile GH patterns). The choice depends on individual goals — With DAC is preferred for long-term regenerative and anti-aging protocols, while Without DAC is preferred when precise timing and natural GH pulse patterns are desired.

Mechanism of Action

The DAC component attaches to plasma albumin, creating a stable reservoir that maintains the peptide's biological activity for 6–8 days. This produces continuous stimulation of growth hormone release from pituitary somatotroph cells, similar in effect to daily HGH injections but with extended pharmacokinetics.

Key Benefits

Extended GH Stimulation — DAC technology provides sustained-release GH stimulation lasting 6–8 days per dose, significantly reducing injection frequency compared to Without DAC (which requires 3+ daily doses).

Regenerative & Anti-Aging Applications — Frequently used in long-term regenerative protocols. Supports muscle maintenance, fat metabolism, bone density, and tissue repair through sustained GH elevation.

Metabolic Enhancement — Promotes lipid metabolism and lean body composition through continuous GH-mediated pathways. Supports overall metabolic efficiency.

Convenient Dosing — Extended half-life allows for significantly less frequent administration compared to other GHRH analogs, improving compliance for long-term use.

References

1. Teichman SL, et al. Prolonged stimulation of growth hormone and insulin-like growth factor I secretion by CJC-1295 in healthy adults. *J Clin Endocrinol Metab.* 2006.
2. Jetté L, et al. Human growth hormone-releasing factor(1-29)-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats. *Endocrinology.* 2005;146(7):3052–3058.
3. Henninge J, et al. Identification of CJC-1295, a growth-hormone-releasing peptide, in an unknown pharmaceutical preparation. *Drug Test Anal.* 2010;2(11–12):647–650.